Richard M Haupt

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Physicians' knowledge and attitudes about rotavirus gastroenteritis and rotavirus vaccine
    Richard M Haupt
    Policy, Public Health, and Medical Affairs, Merck Vaccine Division, PO Box 4 WP97 B352, West Point, PA 19486, USA
    Pediatr Ann 35:54-61. 2006
  2. doi Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection
    Richard M Haupt
    Department of Research, Merck Sharp and Dohme, Corp, Whitehouse Station, NJ, USA
    Int J Cancer 129:2632-42. 2011
  3. doi The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil
    Richard M Haupt
    Vaccine Clinical Research, Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA
    J Adolesc Health 49:467-75. 2011
  4. doi Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women
    Eliav Barr
    Department of Vaccines and Biologics Clinical Research, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Am J Obstet Gynecol 198:261.e1-11. 2008
  5. doi Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
  6. doi Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine
    Adrian Dana
    Merck Research Laboratories, West Point, Pennsylvania 19454 1099, USA
    Obstet Gynecol 114:1170-8. 2009
  7. doi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
  8. doi Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance
    Ralph P Insinga
    Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 20:287-96. 2011
  9. doi Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women
    Liana R Clark
    Department of Global Medical Affairs and Policy, Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    J Adolesc Health 52:322-9. 2013

Detail Information

Publications9

  1. ncbi Physicians' knowledge and attitudes about rotavirus gastroenteritis and rotavirus vaccine
    Richard M Haupt
    Policy, Public Health, and Medical Affairs, Merck Vaccine Division, PO Box 4 WP97 B352, West Point, PA 19486, USA
    Pediatr Ann 35:54-61. 2006
    ..Proof of safety and efficacy, an ACIP/AAP/AAFP recommendation, and private insurance coverage/reimbursement were critical features that would allow physicians to overcome barriers to the adoption of a new rotavirus vaccine...
  2. doi Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection
    Richard M Haupt
    Department of Research, Merck Sharp and Dohme, Corp, Whitehouse Station, NJ, USA
    Int J Cancer 129:2632-42. 2011
    ..Ultimately, population-based surveillance of vaccinated individuals beyond these clinical trials will be required to further address questions regarding the impact of vaccination in women exposed to vaccine HPV types before vaccination...
  3. doi The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil
    Richard M Haupt
    Vaccine Clinical Research, Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA
    J Adolesc Health 49:467-75. 2011
    ..Prophylactic efficacy in other populations (males aged 16-26 years) is also summarized along with long-term safety and efficacy studies...
  4. doi Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women
    Eliav Barr
    Department of Vaccines and Biologics Clinical Research, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Am J Obstet Gynecol 198:261.e1-11. 2008
    ..The purpose of this study was to inform policy regarding human papillomavirus (HPV) vaccination in North America. We measured the clinical impact of HPV-6/-11/-16/-18 vaccination in North American women...
  5. doi Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
    ..Answering the question of which age groups are appropriate to target for catch-up vaccination with the newly licensed quadrivalent HPV vaccine (types 6/11/16/18) will be important for developing vaccine policy recommendations...
  6. doi Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine
    Adrian Dana
    Merck Research Laboratories, West Point, Pennsylvania 19454 1099, USA
    Obstet Gynecol 114:1170-8. 2009
    ....
  7. doi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
    ..We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection...
  8. doi Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance
    Ralph P Insinga
    Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 20:287-96. 2011
    ..We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions...
  9. doi Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women
    Liana R Clark
    Department of Global Medical Affairs and Policy, Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    J Adolesc Health 52:322-9. 2013
    ..Black women are disproportionally diagnosed and have higher mortality from cervical cancer in the United States. Here we describe the prophylactic efficacy and safety of a quadrivalent HPV-6/11/16/18 vaccine in black women...